|
KMID : 1030220210220020091
|
|
Journal of Korean Diabetes
2021 Volume.22 No. 2 p.91 ~ p.96
|
|
|
Dipeptidyl Peptidase 4 Inhibitor, an Update
|
|
Lee Ju-Hee
|
|
|
Abstract
|
|
|
|
Dipeptidyl peptidase 4 (DPP4) inhibitors, one of the most prescribed second-line antidiabetic drugs in South Korea, have been available since 2006. Many studies focusing on the safety profiles of DPP4 inhibitors have been reported. DPP4 inhibitors were associated with a small increased incidence of acute pancreatitis in placebo-controlled trials, although most observational studies did not support this hypothesis. There were no significant differences in major cardiovascular events in a large prospective cardiovascular outcomes trial with DPP4 inhibitors, although a higher risk of hospitalization for heart failure was reported with saxagliptin. Additionally, the safety data of DPP4 inhibitors for diabetes management during the coronavirus disease-19 (COVID-19) pandemic have been provided recently.
|
|
|
KEYWORD
|
|
|
COVID-19, Diabetes mellitus, type 2, Dipeptidyl-peptidase IV inhibitors, Heart failure, Pancreatitis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|